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ABSTRACT
Background Malignant pleural effusion (MPE) causes
debilitating breathlessness and predicting survival is
challenging. This study aimed to obtain contemporary
data on survival by underlying tumour type in patients
with MPE, identify prognostic indicators of overall survival
and develop and validate a prognostic scoring system.
Methods Three large international cohorts of patients
with MPE were used to calculate survival by cell type
(univariable Cox model). The prognostic value of 14
predeﬁned variables was evaluated in the most complete
data set (multivariable Cox model). A clinical prognostic
scoring system was then developed and validated.
Results Based on the results of the international data
and the multivariable survival analysis, the LENT
prognostic score (pleural ﬂuid lactate dehydrogenase,
Eastern Cooperative Oncology Group (ECOG) performance
score (PS), neutrophil-to-lymphocyte ratio and tumour
type) was developed and subsequently validated using an
independent data set. Risk stratifying patients into low-
risk, moderate-risk and high-risk groups gave median
(IQR) survivals of 319 days (228–549; n=43), 130 days
(47–467; n=129) and 44 days (22–77; n=31),
respectively. Only 65% (20/31) of patients with a high-
risk LENT score survived 1 month from diagnosis and just
3% (1/31) survived 6 months. Analysis of the area under
the receiver operating curve revealed the LENT score to be
superior at predicting survival compared with ECOG PS at
1 month (0.77 vs 0.66, p<0.01), 3 months (0.84 vs 0.75,
p<0.01) and 6 months (0.85 vs 0.76, p<0.01).
Conclusions The LENT scoring system is the ﬁrst
validated prognostic score in MPE, which predicts survival
with signiﬁcantly better accuracy than ECOG PS alone.
This may aid clinical decision making in this diverse
patient population.
INTRODUCTION
Malignant pleural effusion (MPE) is common, with
an estimated annual incidence of 150 000 in the
USA alone and given the year-on-year increase in
new cancer diagnoses, the incidence is set to rise.1 2
MPE represents advanced malignant disease and
current guidelines quote median survivals of
between 3 and 12 months.3 Pleural and oncological
treatment options are expanding and hence more
accurate prognostication at presentation may help
individualise treatment strategies.3 4 Treatments may
cause morbidity and necessitate an inpatient stay;
hence, identifying patients with the poorest progno-
sis may help to minimise discomfort and inconveni-
ence at the end of their lives.
A number of factors may help predict survival of
patients with malignant pleural disease, including
tumour characteristics, extent of disease, comorbid-
ities and the composition of the effusion.5–8 In
addition, inﬂammation-based scoring systems have
been associated with overall prognosis in a number
of cancer types, including mesothelioma.9–12
However, until now, no validated score exists to
risk stratify unselected patients with MPE.
The goals of this study were to (a) obtain con-
temporary data on overall survival and survival
according to underlying cell type for patients with
MPE and (b) identify other prognostic indicators of
overall survival in unselected patients with MPE,
with the aim of developing and validating a prog-
nostic scoring system to help inform clinical man-
agement decisions.
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Key messages
What is the key question?
▸ What are the key prognostic indicators in
malignant pleural effusion (MPE) and could
they be used to develop a clinical risk score to
help predict survival and guide management?
What is the bottom line?
▸ Survival of patients with MPE varies greatly
and given the invasive nature of the treatment
options available, better prognostication at
presentation could help select the optimal
management strategy for individual patients.
Why read on?
▸ The LENT score is the ﬁrst validated risk
stratiﬁcation system to predict survival in MPE,
calculated on the basis of pleural ﬂuid lactate
dehydrogenase, Eastern Cooperative Oncology
Group performance score, serum neutrophil-to-
lymphocyte ratio and tumour type.
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METHODS
Three prospectively collected databases from the UK (‘UK
Cohort 1’), Australia (‘Australian Cohort’) and The Netherlands
(‘Dutch Cohort’) were used to identify patients with MPE, who
had been followed up for a minimum of 12 months or until
death (see online supplementary appendix). The three cohorts
comprised of patients presenting with their ﬁrst episode of
MPE, which may have represented a new cancer diagnosis or
recurrence/progression of previously diagnosed malignancy.
A separate ‘UK Cohort 2’ was extracted from the UK database
using patients with MPE entered at a later time point to that of
‘UK Cohort 1’ (see online supplementary appendix). The
patients in ‘UK Cohort 2’ had been followed up for a minimum
of 6 months or until death.
Local ethical approval was obtained for each of the participat-
ing centres and written informed consent was obtained from the
studies’ participants.
Survival time was calculated from the date of diagnosis of
MPE to death (see online supplementary appendix). Subjects
were censored at the time of data extraction or loss to
follow-up.
Patient data from the ‘UK Cohort 1’, ‘Dutch Cohort’ and
‘Australian Cohort’ were amalgamated to evaluate the effect of
underlying cell type on survival, using a univariable Cox model
and Kaplan–Meier survival curves.
Fourteen predeﬁned variables, recorded at the time of presen-
tation with MPE, were then evaluated in ‘UK Cohort 1’ to
ascertain their impact on patient survival. This cohort was
chosen as it had prospectively collected data for the key poten-
tial prognostic variables, minimal missing data and represented
routine, unselected practice in a general hospital making the
ﬁndings widely applicable. Pleural ﬂuid vascular endothelial
growth factor levels and serum N-terminal prohormone of brain
natriuretic peptide (NT-proBNP) levels were quantiﬁed using
stored, frozen samples (see online supplementary appendix).
The NLR was calculated by dividing the blood neutrophil count
by the blood lymphocyte count.
An a priori statistical analysis plan was approved (see online
supplementary appendix). A multivariable, proportional hazard
Cox model with backward selection was performed to deter-
mine which factors were independently predictive of survival.
Variables with a p value >0.1 were removed from the model.
Eighteen (8.1%) patients in ‘UK Cohort 1’ had missing data for
at least one variable; therefore, multiple imputation with 10
imputed data sets was used to account for this, using chained
equations.13 Fractional polynomials were used for continuous
predictors.14
A prognostic scoring system was derived from a subset of
variables, selected based on the data from the international
cohort, the strength of the hazard ratios (HRs) from the multi-
variable analysis of ‘UK Cohort 1’ and their clinical availability.
The prognostic score (‘the LENT score’) was evaluated using
patients with complete data for the four selected variables
from ‘UK Cohort 1’. Overall survival according to the LENT
score was assessed using a Cox model. The area under the
curve (AUC) for 1-month, 3-month and 6-month mortality
and the C statistic were also calculated. The C statistic is a
summary measure of a model’s accuracy, with values ranging
from zero to one.15 Sensitivity analyses were performed to
evaluate the reliability of the score in the following subgroups:
(a) only patients with histo-cytologically conﬁrmed malignancy,
(b) only patients with malignant cell types other than meso-
thelioma, (c) patients with missing data included as both best-
case and worst-case scenarios and (d) only patients with a new
diagnosis of malignant disease, rather than recurrent or pro-
gressive disease.
The LENT score was validated using patients with no missing
data for the four variables included in the LENT score from ‘UK
Cohort 2’. Overall survival was assessed using a Cox model, and
the C statistic and AUC for mortality at 1, 3 and 6 months were
calculated. Sensitivity analyses were conducted, assuming both
best-case and worst-case scenarios for patients with missing
baseline variables.
All analyses were performed using Stata software V.12.1
(Texas, USA).
RESULTS
Obtaining contemporary survival data according to
underlying malignant cell type
Data were obtained on 789 patients (221 patients from ‘UK
Cohort 1’, 253 from the ‘Australian Cohort’ and 315 from the
‘Dutch Cohort’) (see table 1). The mean age was 66.3 (SD 12.9)
years, 53.6% were men and 58.4% of effusions were right
sided. The ‘Dutch Cohort’ contained more women, had a lower
average age and a shorter median survival than the other
cohorts, possibly reﬂecting the smaller proportion of mesotheli-
oma cases. The ‘Australian Cohort’ had a higher proportion of
histo-cytologically proven MPE.
Survival analysis of the combined cohorts showed a large
spread of survival times, ranging from median survivals of
under 50 days in the urological cancer, sarcoma and melanoma
groups, compared with 339 days for those patients with meso-
thelioma (see table 2 and ﬁgure 1). The lung cancer group had a
median survival of only 74 days.
Evaluating other potential prognostic factors
Two hundred and twenty-one patients with a ﬁnal diagnosis of
MPE were included in ‘UK Cohort 1’. One hundred and
ﬁfty-ﬁve of the 221 patients in ‘UK Cohort 1’ had newly diag-
nosed malignancy as opposed to 66 patients where the MPE
represented recurrence or progression of previously diagnosed
cancer.
Based on univariable analysis of the imputed data set, 11 of
the 14 preselected variables showed a statistically signiﬁcant
effect on survival (see online supplementary appendix).
However, multivariable analysis using backward selection identi-
ﬁed effusion size, Eastern Cooperative Oncology Group
(ECOG) performance score (PS), pleural ﬂuid lactate dehydro-
genase (LDH), serum neutrophil-to-lymphocyte ratio (NLR),
serum NT-proBNP and malignant cell type as the only variables
to maintain independent associations with survival at our prede-
ﬁned cut-off of p<0.1 (see online supplementary appendix).
Development of the LENT score
On the basis of clinical applicability and the results of the multi-
variable analysis, we selected four variables (pleural ﬂuid LDH,
ECOG PS, NLR and tumour type) to include in a predictive
model, ‘the LENT score’. Table 3 describes the scoring system,
which results in a score range of 0–7. For ease of interpretation,
patients can be divided into low-risk (score 0–1), moderate-risk
(score 2–4) and high-risk (score 5–7) prognostic groups based
on their LENT score calculated at the time of presentation with
MPE. The Kaplan–Meier survival curves are shown in ﬁgure 2.
Data from 203 patients were used to calculate the summary
statistics for the LENT score (18 were excluded as they had
incomplete data). The Harrell’s C index for the model was
0.71. Patients with moderate-risk and high-risk LENT scores
had HRs (95% CI) for mortality of 1.49 (1.03 to 2.15) and
Lung cancer
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5.97 (3.58 to 9.97) compared with those with a low-risk LENT
score (see ﬁgure 2).
The patients with a low-risk LENT score had a median sur-
vival of 319 days (IQR 228–549; n=43); 100%, 98% and 86%
survived to 1, 3 and 6 months, respectively. Those with a
moderate-risk LENT score had a median survival of 130 days
(47–467; n=129) and 81% survived to 1 month, 59% to
3 months and 47% survived to 6 months. This compares with
those with a high-risk LENT score who had a median survival
of only 44 days (22–77, n=31) and their chances of surviving 1,
3 and 6 months were 65%, 13% and 3%, respectively (see
ﬁgures 3 and 4).
The receiver operating characteristic (ROC) analysis for mor-
tality at 1, 3 and 6 months using the LENT score gave signiﬁ-
cantly higher AUC values than ECOG performance status alone.
The AUC at 1 month was 0.77 (95% CI 0.70 to 0.84) for
LENT compared with 0.66 (0.57 to 0.75) for ECOG PS
(p=0.005). At 3 months, the AUC for LENTwas 0.84 (0.79 to
0.89) compared with 0.75 (0.69 to 0.81) for ECOG PS
(p<0.001). At 6 months, the AUC for LENTwas 0.85 (0.80 to
0.90) compared with 0.76 (0.70 to 0.82) for ECOG PS
(p=0.001) (see ﬁgure 4).
All sensitivity analyses performed using ’UK Cohort 1’
showed the results to be robust (see online supplementary
appendix).
Validation of the LENT score
Seventy-six of the 83 patients in ‘UK Cohort 2’ were used for
the validation (two patients had missing data for PS, three for
ﬂuid LDH, one for tumour type and one for NLR).
Multivariable analysis evaluating the four components of the
LENTscore using ‘UKCohort 2’ showed that ECOG performance
and NLR were independent predictors of mortality at the prede-
ﬁned cut-off of p<0.1 (see online supplementary appendix).
Survival analysis of ‘UK Cohort 2’ revealed that the LENT
risk groups had similar HR for mortality as ‘UK Cohort 1’ (see
ﬁgure 2). Harrell’s C statistic for ‘UK Cohort 2’ was better than
that of ‘UK Cohort 1’ (0.75 and 0.71, respectively) and the
Table 1 Baseline characteristics of the UK, Australian and Dutch cohorts
UK Cohort 1
n=221
Australian Cohort
n=253
Dutch Cohort
n=315
UK Cohort 2
n=83
Age, median (IQR) 74 (67–80) 69 (63–78) 60 (53–66) 71 (61–76)
% Men 62.0 65.6 38.1 60.2
% Right sided 57.0 61.0 57.3 63.9
Mode of diagnosis, n (%)
Pleural cytology, flow cytometry or pleural biopsy 150 (68) 205 (81) 213 (68) 54 (65)
Otherwise unexplained effusion with confirmed malignancy elsewhere 54 (24) 48 (19) 102 (32) 25 (30)
Radiological evidence of malignancy with no histo-cytological proof 17 (8) 0 0 4 (5)
Cell type, n (%)
Mesothelioma 58 (26) 96 (38) 16 (5) 17 (20)
Lung cancer 66 (30) 72 (28) 77 (24) 33 (40)
Gynaecological cancer 20 (9) 17 (7) 22 (7) 4 (5)
Breast cancer 26 (12) 25 (10) 89 (28) 11 (13)
Gastrointestinal cancer 10 (5) 8 (3) 43 (14) 3 (4)
Haematological malignancy 13 (6) 15 (6) 7 (2) 7 (8)
Other 28 (13) 20 (8) 61 (19) 8 (10)
Overall median survival, days (95% CI) 168 (108 to 228) 205 (167 to 238) 84 (72 to 115) 193 (97 to 332)
Table 2 Median survival according to cell type for the UK,
Australian and Dutch cohorts combined
Cell type
Median survival in days
(95% CI) n
Mesothelioma 339 (267 to 422) 170
Haematological malignancy 218 (160 to 484) 35
Gynaecological malignancy 203 (97 to 279) 59
Breast cancer 192 (133 to 271) 140
Renal cell carcinoma 114 (33 to 334) 22
Adenocarcinoma of unknown primary 87 (13 to 286) 11
Lung cancer 74 (60 to 92) 215
Other 71 (46 to 102) 33
Gastrointestinal cancer 61 (44 to 73) 61
Sarcoma 44 (19 to 76) 12
Melanoma 43 (23 to 72) 23
Urological cancer (bladder, prostate,
testis, penile)
33 (22 to 168) 8
Overall 136 (119 to 167) 789 Figure 1 Kaplan–Meier survival curves according to cell type for the
UK, Australian and Dutch cohorts combined.
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proportion of patients surviving to 1, 3 and 6 months was com-
parable with that of ‘UK Cohort 1’ (see ﬁgure 3).
The ROC analysis for ‘UK Cohort 2’ again gave higher AUC
values for the LENT score than for ECOG PS. At 1 month, the
AUC for the LENT score was 0.78 (95% CI 0.64 to 0.92) com-
pared with 0.69 (0.46 to 0.92) for ECOG PS (p=0.360). At
3 months, the AUCs for the LENT score and ECOG PS were
0.76 (0.65 to 0.86) and 0.62 (0.49 to 0.74), respectively
(p=0.002). The AUC at 6 months for the LENT score was also
signiﬁcantly better than ECOG PS (0.81 (0.72 to 0.90) and
0.65 (0.54 to 0.77), respectively) (p<0.001; see ﬁgure 4).
A sensitivity analysis was performed, which revealed no
important differences when including patients with missing data
as either the best-case or worst-case scenarios (see online supple-
mentary appendix).
DISCUSSION
This study is the largest prospectively collected series in the litera-
ture to evaluate prognostic factors in patients with MPE. We have
developed the ﬁrst validated risk stratiﬁcation system for this
diverse patient group (the LENT score), which provides valuable
additional prognostic information for doctors and patients and
performs signiﬁcantly better than ECOG performance status
alone. This information is of direct clinical relevance in tailoring
treatment strategies according to an individual’s predicted survival.
Our prospective, contemporary and internationally relevant
data support data from previous smaller series highlighting the
wide range of survivals in this population according to malig-
nant cell type.6 16 The sizeable difference in median survival
between, for example, mesothelioma (339 days) and lung cancer
(74 days) is likely to signiﬁcantly alter the choice of manage-
ment in these patients. Interestingly, the overall median survival
for our entire cohort is not dissimilar to older studies, highlight-
ing that despite oncological advances, outcomes have not sub-
stantially improved for these patients.6 16
Multivariable analysis of ‘UK Cohort 1’ highlighted poten-
tially important roles for local and systemic inﬂammation in pre-
dicting survival, independent of the more predictable
associations with cell type and ECOG PS.7 8
Our data support previous work indicating that high pleural
ﬂuid LDH levels (reﬂecting localised, acute inﬂammation, necro-
sis and cell death within the pleural cavity) are indicative of a
poor prognosis in MPE.6 17 Acute, neutrophilic tumour inﬁltra-
tion has also been shown to confer a worse prognosis in
mesothelioma.18
The highly signiﬁcant association between NLR and survival
supports data from other cancer types, including mesothelioma,
suggesting that systemic inﬂammation is also an important prog-
nostic factor.11 12 19 This is consistent with the growing
Figure 2 Survival curves according to the LENT score. (A) ‘UK Cohort 1’ and (B) ‘UK Cohort 2’. MS, median survival; IQR, interquartile range; HR,
hazard ratio; 95% CI, 95% conﬁdence interval; NA*, Unable to provide data as insufﬁcient patients have died.
Table 3 The LENT score calculation
Variable Score
L LDH level in pleural fluid (IU/L)
<1500 0
>1500 1
E ECOG PS
0 0
1 1
2 2
3–4 3
N NLR
<9 0
>9 1
T Tumour type
Lowest risk tumour types
▸ Mesothelioma
▸ Haematological malignancy
0
Moderate risk tumour types
▸ Breast cancer
▸ Gynaecological cancer
▸ Renal cell carcinoma
1
Highest risk tumour types
▸ Lung cancer
▸ Other tumour types
2
Risk categories Total score
Low risk 0–1
Moderate risk 2–4
High risk 5–7
ECOG PS, Eastern Cooperative Oncology Group performance score; LDH, lactate
dehydrogenase; NLR, neutrophil-to-lymphocyte ratio.
Lung cancer
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evidence that systemic inﬂammation may contribute to both
morbidity (in the form of constitutional symptoms) and mortal-
ity in cancer and may represent a common pathway in the fatal
progression of malignancy.10 Along with the presence of under-
lying comorbidities (such as cardiac or renal failure), the sys-
temic inﬂammatory response may also contribute to the poorer
prognosis we have identiﬁed in those patients with higher
NT-proBNP levels through increasing cardiac work.
NLR is simply calculated from a full blood count and hence is
cheap and universally available, making it an attractive potential
biomarker. Further work is necessary to understand the
mechanisms behind its prognostic value and why it appears to
prognosticate better than other inﬂammatory markers.
Data from two, large randomised controlled trials (RCTs)
evaluating treatment strategies in MPE suggest that clinicians are
inaccurate at predicting survival in this population. In the
TIME2 trial, 36/106 participants (34%) died within 3 months
of trial entry (despite an exclusion criteria for trial entry of pre-
dicted survival of <3 months) and 58/340 (17%) of patients
died within 30 days of trial entry to the Dresler et al study
(who only included patients with a predicted survival of
>2 months).20 21 This highlights that clinical judgement alone is
Figure 4 Receiver operating characteristic (ROC) curve analysis for the LENT score and Eastern Cooperative Oncology Group (ECOG) performance
score (PS) for the outcome of mortality. (A)‘UK Cohort 1’ at 1 month. (B)‘UK Cohort 1’ at 3 months. (C) ‘UK Cohort 1’ at 6 months. (D)‘UK Cohort 2’
at 1 month. (E) ‘UK Cohort 2’ at 3 months. (F) ‘UK Cohort 2’ at 6 months.
Figure 3 Proportion of patients
surviving to 1, 3 and 6 months
according to low-risk, moderate-risk
and high-risk LENT scores. (A) ‘UK
Cohort 1’ and (B) ‘UK Cohort 2’.
Lung cancer
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imprecise at estimating patient survival. In addition, the ECOG
performance status of patients with MPE may vary as the effu-
sion is managed and hence solely relying only on this to predict
prognosis may be suboptimal.
Attempts have been made in a number of cancer types to
develop prognostic scoring systems for this purpose.9 10 In meso-
thelioma, the European Organisation for Research and
Treatment of Cancer and Cancer and Leukaemia Group B scores
have been developed, but no scoring system exists for all-comers
with MPE.22 23
In order for the LENT score to be clinically useful and easy to
calculate, we selected four variables to include in the score,
which are readily available in the clinical setting and had highly
signiﬁcant associations with survival from the multivariable ana-
lysis. We have shown the LENT score to be particularly effective
at identifying patients with the worst prognosis and that it is sig-
niﬁcantly better than ECOG PS alone at identifying these
patients.
This is important to help patients and clinicians select an
optimal management strategy. Patients with a particularly poor
prognosis may wish to minimise time spent in hospital by
choosing an indwelling pleural catheter or therapeutic pleural
aspiration over attempted pleurodesis to manage their effu-
sion.20 Previous studies report the median length of hospital
stay of between 4 and 6 days for inpatient talc pleurodesis,
which for patients with a high LENT score would represent a
substantial proportion of their remaining life, given their
median survival in this study of only 44 days.20 24
Additionally, a robust clinical risk score is likely to be invalu-
able in future RCTs in this area. The LENT score could be used
as an eligibility criterion to select patients likely to survive sufﬁ-
cient time for the primary endpoint analysis, thereby ensuring
studies remain suitably powered. It could also be used to
balance randomisation groups in the clinical trial setting as a
stratiﬁcation/minimisation criterion.25
The strengths of this study include its large sample size and
the prospective nature of the case series. By including all
patients in the survival analysis and accounting for missing data
using multiple imputation or sensitivity analyses, we have
ensured that all available data are used and the potential of
missing important associations by using complete case data is
minimised. We have also validated our risk model using an inde-
pendent data set, which adds strength to our ﬁndings. The
LENT scoring system is less subjective than PS alone and relies
on readily available tests, allowing it to be rapidly calculated
without additional costs. Additionally, as the LENT score has
been developed using patients presenting with their ﬁrst episode
of MPE, regardless of previous cancer treatment, it is widely
applicable and relevant in the clinical setting.
There are some limitations to the study. The LENT score has
been developed using patients with robust diagnoses of MPE
and hence may not be generalised to all patients with clinically
suspected MPE or para-malignant effusions. We lacked data on
the extent that patients had been pretreated for their malignancy
and only had data for ‘UK Cohort 1’ on whether their effusion
represented a new malignant diagnosis or recurrent/progressive
disease. These factors may impact on survival, particularly in
certain cell types such as breast cancer. Due to the diverse
staging systems for the different pleural tumours, and the lack
of a universal biomarker, it was not possible to include the
extent of disease in our analysis. This would be interesting to
evaluate in future studies as the associations between NLR and
ﬂuid LDH with survival, for example, may be surrogates for
tumour burden.
The predominance of mesothelioma cases in this study reﬂects
the high incidence of this tumour in the UK and Western
Australia. However, sensitivity analysis found the predictive
value of the LENT score remained robust when these patients
were excluded, suggesting it is also a valid tool in populations
with a lower incidence of mesothelioma. Additionally, given the
size of the ‘UK Cohort 2’, further endorsement with another
prospectively collected data set would be beneﬁcial before the
LENT score is introduced to standard clinical practice.
This is the largest prospectively collected series in the litera-
ture evaluating prognostic factors in MPE. It highlights the dis-
parate survival prospects in this population and identiﬁes
markers of local and systemic inﬂammation as key prognostic
indicators. The LENT score is the ﬁrst validated risk stratiﬁca-
tion system in MPE and is signiﬁcantly better than ECOG PS at
predicting survival. It is a robust, easy to calculate, clinically
relevant prognostic score, which may help discussions with
patients about prognosis and thereby guide the selection of
appropriate treatment pathways.
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